An investigation for investors in NASDAQ:NLNK shares was announced concerning potential breaches of fiduciary duties by certain NewLink Genetics directors.
Investors who are current long term investors in NewLink Genetics Corp (NASDAQ:NLNK) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm for investors in NASDAQ:NLNK stocks follows a lawsuit pending against NewLink Genetics over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ:NLNK stocks, concerns whether certain NewLink Genetics directors are liable in connection with the allegations made in that lawsuit.
The plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose thatthe Company’s algenpantucel-L treatment was ineffective and potentially harmful to patients, and that as a result of the foregoing, NewLink’s public statements were materially false and misleading at all relevant times.
On May 09, 2016, NewLink Genetics Corp (NASDAQ:NLNK) announced the results of its Phase 3 clinical trial for algenpantucel-L for patients with resected pancreatic cancer. NewLink Genetics Corp said that the IMPRESS Phase 3 study of algenpantucel-L for patients with resected pancreatic cancer did not achieve its primary endpoint. Shares of NewLink Genetics Corp (NASDAQ:NLNK) declined from $54.24 per share in September 2015 to as low as $9.23 per share on May 12, 2016.
Those who purchased NASDAQ:NLNK shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com